Company News
Intellia Shares Drop 3% After Positive Trial
Intellia Therapeutics shares fell 3% on Monday despite earlier rise after announcing positive Phase 3 HAELO trial results.
The trial of lonvo‑z (lonvoguran ziclumeran) reduced hereditary angioedema at
